指南与共识结核与非结核分枝杆菌

少见非结核分枝杆菌肺病的共识管理建议

Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases.
指南 / 共识 · Lancet Infect Dis · 2022-01-25

美国胸科学会、欧洲呼吸学会、欧洲临床微生物学与感染病学会及美国感染病学会2020年指南与英国胸科学会2017年指南仅覆盖鸟分枝杆菌复合群、堪萨斯分枝杆菌、蟾蜍分枝杆菌和脓肿分枝杆菌所致成人肺病。本专家小组通过系统文献检索,为无囊性纤维化或HIV感染的成人中由龟分枝杆菌、偶发分枝杆菌、日内瓦分枝杆菌、戈登分枝杆菌、玛尔摩分枝杆菌、猿分枝杆菌和舒尔加分枝杆菌七种少见非结核分枝杆菌所致的肺病提供管理指导,治疗建议经结构化共识流程制定。

要点

  • 证据总体质量极低,主要基于病例报告和病例系列
  • 仅玛尔摩分枝杆菌有随机对照试验和回顾性队列研究支持
  • 建议覆盖龟、偶发、日内瓦、戈登、玛尔摩、猿和舒尔加分枝杆菌

核心结论

  • 针对七种少见非结核分枝杆菌所致肺病的治疗建议经结构化共识流程制定,但支持证据总体质量极低。

研究设计与样本

  • 美国胸科学会、欧洲呼吸学会、欧洲临床微生物学与感染病学会和美国感染病学会2020年指南及英国胸科学会2017年指南覆盖鸟分枝杆菌复合群、堪萨斯分枝杆菌、蟾蜍分枝杆菌和脓肿分枝杆菌肺病。
  • 专家小组通过系统文献检索,为无囊性纤维化或HIV感染的成人中七种少见非结核分枝杆菌所致肺病提供管理指导,建议经结构化共识流程制定。

主要发现

  • 除玛尔摩分枝杆菌外,其他非结核分枝杆菌所致肺病治疗建议的英文文献证据质量极低,基于病例报告和病例系列的评估。
  • 玛尔摩分枝杆菌有两项随机对照试验和三项回顾性队列研究结果提供较好的治疗建议证据基础,但证据质量仍低。

关键数值与推荐

  • 治疗建议针对龟分枝杆菌、偶发分枝杆菌、日内瓦分枝杆菌、戈登分枝杆菌、玛尔摩分枝杆菌、猿分枝杆菌和舒尔加分枝杆菌所致肺病。
  • 证据质量:除玛尔摩分枝杆菌外为极低质量;玛尔摩分枝杆菌为低质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 除玛尔摩分枝杆菌外,其他非结核分枝杆菌肺病治疗建议的证据质量极低,基于病例报告和病例系列。
  • 玛尔摩分枝杆菌证据质量仍低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2020 clinical practice guideline for the treatment of non-tuberculous mycobacterial pulmonary disease (NTM-PD) by the American Thoracic Society, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases, and Infectious Diseases Society of America; and the 2017 management guideline by the British Thoracic Society covered pulmonary diseases in adults caused by Mycobacterium avium complex, Mycobacterium kansasii, Mycobacterium xenopi, and Mycobacterium abscessus. In order to provide evidence-based recommendations for the treatment of less common non-tuberculous mycobacterial (NTM) species in adult patients without cystic fibrosis or HIV infection, our expert panel group performed systematic literature searches to provide management guidance for pulmonary diseases caused by seven additional organisms: Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium genavense, Mycobacterium gordonae, Mycobacterium malmoense, Mycobacterium simiae, and Mycobacterium szulgai. Treatment recommendations were developed by a structured consensus process. The evidence from the scientific literature published in English for treatment recommendations for pulmonary diseases caused by other NTM species was of very low quality, with the exception of M malmoense, and based on the evaluation of case reports and case series. For M malmoense, results from two randomised controlled trials and three retrospective cohort studies provided a better evidence base for treatment recommendations, although the evidence was still of low quality.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lange C, Böttger EC, Cambau E, et al. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis. 2022. PMID: 35090639. doi:10.1016/S1473-3099(21)00586-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。